KAND 145
Alternative Names: KAND-145Latest Information Update: 28 Apr 2025
At a glance
- Originator Kancera
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Chemokine CXCL13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ovarian cancer
- Preclinical Chronic lymphocytic leukaemia
- No development reported Inflammation
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Ovarian-cancer in Sweden (IV)
- 03 May 2024 Efficacy and adverse event data from a phase I trials in healthy volunteers released by Kancera
- 08 Apr 2024 Kancera completes a Phase-I clinical trials in Ovarian cancer (In volunteers) in Finland (PO) (NCT06063343)